-
1.
公开(公告)号:US07612094B2
公开(公告)日:2009-11-03
申请号:US10510459
申请日:2003-04-04
申请人: Wen-Cherng Lee , Lihong Sun , Feng Shan , Claudio Chuaqui , Zhongli Zheng , Russell C. Petter
发明人: Wen-Cherng Lee , Lihong Sun , Feng Shan , Claudio Chuaqui , Zhongli Zheng , Russell C. Petter
IPC分类号: A61K31/4545 , C07D401/14
CPC分类号: C07D471/04 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D487/08
摘要: Compounds of formula (I) possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.In one embodiment, the invention features a compound of the general formula (I).
摘要翻译: 式(I)化合物对Alk 5和/或Alk 4具有出人意料的高亲和力,并且可用作其拮抗剂,用于预防和/或治疗包括纤维化疾病在内的许多疾病。 在一个实施方案中,本发明的特征在于通式(I)的化合物。
-
公开(公告)号:US06630503B1
公开(公告)日:2003-10-07
申请号:US09638652
申请日:2000-08-14
IPC分类号: A61K3140
CPC分类号: C07D401/06 , A61K38/00 , C07D205/04 , C07D207/16 , C07D207/48 , C07D209/42 , C07D211/32 , C07D265/30 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07K5/0215 , C07K5/06165 , C07K5/06191
摘要: A cell adhesion inhibitor of the general formula: R3—L—L′—R1 is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, as well as pharmaceutical compositions containing the same.
摘要翻译: 公开了通式的细胞粘附抑制剂。 本发明的抑制剂与VLA-4分子相互作用并抑制VLA-4依赖性细胞粘附。 还公开了制备和使用这种细胞粘附抑制剂的方法以及含有该细胞粘附抑制剂的药物组合物。
-
公开(公告)号:US07034043B2
公开(公告)日:2006-04-25
申请号:US10677756
申请日:2003-10-03
IPC分类号: A61K31/445 , C07D211/60
CPC分类号: C07D401/06 , A61K38/00 , C07D205/04 , C07D207/16 , C07D207/48 , C07D209/42 , C07D211/32 , C07D265/30 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07K5/0215 , C07K5/06165 , C07K5/06191
摘要: A cell adhesion inhibitor of the general formula: R3-L-L′-R1 is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, as well as pharmaceutical compositions containing the same.
摘要翻译: 具有以下通式的细胞粘附抑制剂:<?in-line-formula description =“In-line Formulas”end =“lead”?> R 3 -L-L'-R 1 SUP> <?in-line-formula description =“In-line Formulas”end =“tail”?>被公开。 本发明的抑制剂与VLA-4分子相互作用并抑制VLA-4依赖性细胞粘附。 还公开了制备和使用这种细胞粘附抑制剂的方法以及含有该细胞粘附抑制剂的药物组合物。
-
公开(公告)号:US07196112B2
公开(公告)日:2007-03-27
申请号:US10892400
申请日:2004-07-16
IPC分类号: A61K31/4025 , A61K31/401 , C07D207/48
CPC分类号: C07K5/06165
摘要: Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.
-
公开(公告)号:US08741837B2
公开(公告)日:2014-06-03
申请号:US13620573
申请日:2012-09-14
申请人: Deqiang Niu , Russell C. Petter , Juswinder Singh , Arthur F. Kluge , Lixin Qiao
发明人: Deqiang Niu , Russell C. Petter , Juswinder Singh , Arthur F. Kluge , Lixin Qiao
CPC分类号: C07K5/081 , A61K38/00 , C07K5/0202 , C07K5/06165 , C07K5/0804 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0815 , C07K5/0821 , C12N9/506 , C12N9/96 , C12N9/99
摘要: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
摘要翻译: 本发明提供化合物,其药学上可接受的组合物及其使用方法。
-
公开(公告)号:US08586600B2
公开(公告)日:2013-11-19
申请号:US13485037
申请日:2012-05-31
IPC分类号: C07D403/12 , C07D403/14 , C07D401/12 , C07D401/14 , A61K31/506 , A61P35/00 , A61P19/02
CPC分类号: C07D401/04 , A61K31/444 , A61K31/506 , A61K45/06 , C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
-
公开(公告)号:US08524760B2
公开(公告)日:2013-09-03
申请号:US13443847
申请日:2012-04-10
申请人: Deqiang Niu , Russell C. Petter , Lixin Qiao , Juswinder Singh
发明人: Deqiang Niu , Russell C. Petter , Lixin Qiao , Juswinder Singh
IPC分类号: A61K31/40 , C07D209/52
CPC分类号: C07K7/06 , A61K31/40 , A61K31/403 , A61K31/4439 , A61K31/4965 , A61K31/506 , A61K38/00 , A61K38/06 , A61K38/07 , A61K38/08 , A61K45/06 , C07D209/52 , C07D401/12 , C07D403/12 , C07K5/06165 , C07K5/0802 , C07K5/0804 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/0821 , C07K5/0827 , C07K5/1016 , C12N9/506 , C12N9/99 , C12Y304/21098
摘要: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
-
公开(公告)号:US08445498B2
公开(公告)日:2013-05-21
申请号:US13018624
申请日:2011-02-01
IPC分类号: A01N43/54
CPC分类号: C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D239/47 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D471/04 , C12N9/12 , C12Y207/10
摘要: The present invention provides 4,6-disubstituted pyrimidine compound useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
摘要翻译: 本发明提供可用作激酶抑制剂的4,6-二取代的嘧啶化合物,其药学上可接受的组合物及其使用方法。
-
公开(公告)号:US08293705B2
公开(公告)日:2012-10-23
申请号:US12497122
申请日:2009-07-02
申请人: Deqiang Niu , Russell C. Petter , Juswinder Singh , Arthur F. Kluge , Lixin Qiao
发明人: Deqiang Niu , Russell C. Petter , Juswinder Singh , Arthur F. Kluge , Lixin Qiao
IPC分类号: A61K38/00
CPC分类号: C07K5/081 , A61K38/00 , C07K5/0202 , C07K5/06165 , C07K5/0804 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0815 , C07K5/0821 , C12N9/506 , C12N9/96 , C12N9/99
摘要: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
-
公开(公告)号:US20120149687A1
公开(公告)日:2012-06-14
申请号:US13286061
申请日:2011-10-31
IPC分类号: A61K31/5377 , C07D239/34 , C07D413/12 , C07D403/12 , A61K31/506 , C07D295/155 , A61K31/5375 , A61K31/551 , C07D267/10 , A61K31/553 , C07D417/12 , A61K31/541 , A61P35/00 , C12N5/09 , C07D239/42
CPC分类号: A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D239/34 , C07D239/42 , C07D239/47 , C07D239/48 , C07D403/14
摘要: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
-
-
-
-
-
-
-
-
-